ロード中...
Bortezomib for the treatment of mantle cell lymphoma: an update
Bortezomib is a first in class proteasome inhibitor, initially approved by the US Food and Drug Administration for the treatment of plasma cell myeloma. Bortezomib has been approved for the treatment of relapsed and refractory mantle cell lymphoma (MCL) and, more recently, in the upfront setting as...
保存先:
| 出版年: | Ther Adv Hematol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959639/ https://ncbi.nlm.nih.gov/pubmed/27493710 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716648566 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|